Recent News

• 12.11.2025 - Immunovant Announces Pricing of $550 Million Common Stock Financing
• 11.10.2025 - Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
• 10.27.2025 - Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Recent Filings

• 12.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.11.2025 - 8-K Current report
• 12.11.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 144 Report of proposed sale of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities